Niagen Bioscience (NAGE) Equity Ratio (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Equity Ratio data on file, last reported at 0.72 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.72, up 5.83% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.72 (up 5.83% YoY), and the FY2025 annual result was 0.72, up 6.54% from the prior year.
• Equity Ratio steadied at 0.72 in Q1 2026 per NAGE's latest filing, from 0.72 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.72 in Q3 2025 and troughed at 0.45 in Q2 2022.
• A 5-year average of 0.58 and a median of 0.54 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio plunged 30.36% in 2022, then surged 30.4% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.53 in 2022, then dropped by 2.39% to 0.52 in 2023, then surged by 30.4% to 0.68 in 2024, then advanced by 6.54% to 0.72 in 2025, then increased by 0.12% to 0.72 in 2026.
• Business Quant data shows NAGE's Equity Ratio at 0.72 in Q1 2026, 0.72 in Q4 2025, and 0.72 in Q3 2025.